235 related articles for article (PubMed ID: 31564914)
1. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring
Han S; Fang J; Lu S; Wang L; Li J; Cheng M; Ren Y; Su W
Onco Targets Ther; 2019; 12():7323-7328. PubMed ID: 31564914
[TBL] [Abstract][Full Text] [Related]
2. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
3. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
[TBL] [Abstract][Full Text] [Related]
4. Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.
Zhang Y; Zhang H; Wang H; Zeng J; Zhang B; Zhou N; Zu L; Song Z; Wang C; Xu S
Front Oncol; 2022; 12():968030. PubMed ID: 36176406
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring
Yu Y; Ren Y; Fang J; Cao L; Liang Z; Guo Q; Han S; Ji Z; Wang Y; Sun Y; Chen Y; Li X; Xu H; Zhou J; Jiang L; Cheng Y; Han Z; Shi J; Chen G; Ma R; Fan Y; Sun S; Jiao L; Jia X; Wang L; Lu P; Xu Q; Luo X; Su W; Lu S
Ther Adv Med Oncol; 2022; 14():17588359221133546. PubMed ID: 36339926
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
Front Oncol; 2022; 12():954886. PubMed ID: 36052259
[No Abstract] [Full Text] [Related]
7. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
Zhu X; Lu Y; Lu S
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551608
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report.
Gu L; Wei X; Zhang Z; Heng W
Clin Med Insights Oncol; 2022; 16():11795549211067185. PubMed ID: 35110965
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
10. MET alterations in advanced pulmonary sarcomatoid carcinoma.
Gong C; Xiong H; Qin K; Wang J; Cheng Y; Zhao J; Zhang J
Front Oncol; 2022; 12():1017026. PubMed ID: 36212500
[TBL] [Abstract][Full Text] [Related]
11. Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion.
Ouyang G; Shu P; Xue Y; Luo F; Li Y
Onco Targets Ther; 2024; 17():79-84. PubMed ID: 38313385
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Fan S; Yu J; Lu P; Luo X; Su W
JTO Clin Res Rep; 2022 Oct; 3(10):100407. PubMed ID: 36217329
[TBL] [Abstract][Full Text] [Related]
14. Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation.
Ren X; Li K; Zhang Y; Zou C; Su M
Front Oncol; 2024; 14():1297156. PubMed ID: 38380365
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer.
Song Y; Li G; Ju K; Ran W; Zhao H; Liu X; Hou M; He Y; Chen Y; Zang G; Xing X
Front Oncol; 2021; 11():755031. PubMed ID: 34660325
[TBL] [Abstract][Full Text] [Related]
16. Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib.
Li J; Feng Y; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():863560. PubMed ID: 35444936
[TBL] [Abstract][Full Text] [Related]
17. Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline
Jiao Y; Fang C; Yang Y; Shao L; Huang Y; Sun Q; Dong Y
Onco Targets Ther; 2021; 14():2417-2421. PubMed ID: 33854337
[No Abstract] [Full Text] [Related]
18. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.
Lim SM; Yang SD; Lim S; Shim HS; Cho BC
JTO Clin Res Rep; 2021 Jun; 2(6):100180. PubMed ID: 34590028
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
